Blog · Evidence, in plain language

At-home brain stimulation for depression: what we tell patients.

Patients have begun asking about a headset that treats depression at home. One such device received full FDA approval in December 2025, and the story around it is more balanced than either the marketing or the mockery suggests: a positive trial, a regulator that approved it while stating its uncertainty in writing, and specialists who say the evidence is not there yet. This is the summary we give.

By Karel Winner, DNP, PMHNP-BC · Published November 17, 2026

This post is education from the practice, not medical advice. It summarizes a regulator decision and published research. It is not a recommendation about any individual care, and it makes no promise that this practice will prescribe or supply the device discussed.

The short answer

The device is the Flow FL-100, from Flow Neuroscience AB. It delivers transcranial direct current stimulation, a low-intensity direct current through scalp electrodes. On December 8, 2025, the FDA granted it premarket approval P230024 for the treatment of moderate to severe major depressive disorder in the current episode, as monotherapy or as an adjunctive treatment, in patients 18 years and older who are not considered treatment refractory to medication. A Brain Stimulation editorial identifies it as the first FDA premarket approval for a home-use non-invasive brain stimulation device specifically indicated for depression. In its pivotal trial, 174 adults treated at home for 10 weeks improved more on active stimulation than on a sham device: 9.41 against 7.14 points on the Hamilton Depression Rating Scale, with remission in 44.9 percent against 21.8 percent on that scale.

What we are careful about

The FDA approval document states, in its limitations section, that there is a moderate level of uncertainty of benefit, citing unblinding, the lack of a prespecified clinically significant change in Hamilton scores, and conflicting results from the literature. In the trial, 77.6 percent of the active group correctly guessed their treatment, against 40.7 percent correct guesses in the sham group. Adjusted for that imbalance, the FDA estimated the advantage at about 2.0 to 2.12 points rather than 2.3. A 2026 commentary in The Lancet Psychiatry argues the approval is not yet scientifically justified and that misuse and unsupervised use risks have not been addressed. We also note the boundaries of the approval itself: it does not cover adolescents, bipolar depression, or depression considered resistant to medication, and no trial compared the device directly with an antidepressant, with psychotherapy, or with clinic-based stimulation. Side effects in the study were mainly skin irritation, redness, stinging or tingling during sessions, headache, and, importantly, acute mood change or worsening depression in some cases, which is why any use belongs inside monitored care.

How it fits care here

Depression is a condition this practice treats, with medication management and, where it belongs in the plan, therapy. A home device changes the setting of one kind of treatment. It does not change the questions that decide a plan: how severe and how persistent the episode is, what has already been tried and for how long, what else is on the treatment list, and how closely progress will be measured. For a patient whose current treatment is working, this news changes nothing. For a patient whose treatment is not working, the first task is still to name the specific failure, because the approved group for this device excludes the treatment refractory patients who most often ask about new options. Whether this device suits a particular patient is a visit decision, made with their full history in view, and we make no claim for the product beyond what the approval, the trial, and the published critique state, including the disagreement among them.

Read more, by door

Each clinical site in this practice keeps its own blog, and each has written this topic for its own readers. For the medication focused read, PsychMed Care has published at-home brain stimulation for depression, what was approved, covering the indication, the trial numbers, and the safety list in detail. For the combined therapy and medication perspective, psych.us has published brain stimulation at home for depression, a careful look, including what a home routine demands and where therapy fits beside a device. When reading has done all it can, the booking page is the next step.

Sources

The summary above rests on the regulator and journal sources below.

U.S. Food and Drug Administration, Summary of Safety and Effectiveness Data, Premarket Approval P230024, Flow FL-100, notice of approval December 8, 2025: the approved indication, the device description, the Empower study results, the blinding analysis, the adverse effects, and the FDA statement of moderate uncertainty of benefit. FDA Summary of Safety and Effectiveness Data.

Woodham and colleagues, Nature Medicine (2025), volume 31, pages 87 to 95: a fully remote, multisite, double-blind, placebo-controlled randomized trial of 10-week home-based transcranial direct current stimulation in major depressive disorder, 174 participants, ClinicalTrials.gov NCT05202119. PubMed record.

Bikson, Brunoni, and George, Brain Stimulation (2026), volume 19, article 103021: the approval is the first FDA premarket approval for a home-use non-invasive brain stimulation device specifically indicated for depression treatment. PubMed record.

Commentary in The Lancet Psychiatry (2026): US FDA premarket approval of tDCS depression treatment is not yet scientifically justified. The authors argue the efficacy evidence is not convincing and that risks from misuse and unsupervised use have not been addressed. The Lancet Psychiatry.

Please read this part

This post is educational and does not create a treatment relationship. The trial summarized here enrolled 174 adults who were not considered resistant to medication, and ran for 10 weeks, so it cannot predict how any one person will respond or how this device compares with a treatment already working for them. Patients of this practice who want to discuss depression treatment options should raise the question at a visit, where their diagnosis, history, and full treatment list can be weighed.

If you are having thoughts of harming yourself, help is available now: call or text 988, text HOME to 741741 for Crisis Text Line, or call the NAMI Helpline at 1-800-950-6264. This practice is not an emergency service. If someone is in immediate danger, call 911. The crisis page lists more options.

Begin with the booking page.

New patient Comprehensive Initial Appointments run 60 minutes. Follow-up Appointments run 30. Booking happens on IntakeQ, and every plan is verified before the first visit.